Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

FDA Posts Investigator In Singapore, But Trims Foreign Office List

This article was originally published in The Tan Sheet

Executive Summary

FDA's Office of International Programs consolidates its China offices to "strategically focus its resources." FDA shifts away from primarily a domestic focus to global as drug criminal organizations spread globally


Related Content

FDA Mutual Reliance With EU On Inspections Is Slow Going
FDA’s New Criminal Investigations Chief Wants Global Reach
FDA Field Operations Would Endure Reductions Under Budget
FDA Plans To Rely On Non-U.S. Regulators In Global Drug Quality Initiative
FDA Closing Office In Jordan To Better Leverage Shrinking Resources





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst